Contraceptive gel maker Evofem kicks off strategic review

After winning an FDA approval for its contraceptive gel Phexxi back in 2020, San Diego's Evofem Biosciences is launching a strategic review.

Thursday, Evofem said its board has unanimously voted to start reviewing options for the company. Potential strategic options might include a merger, asset sales or a potential licensing deal, the company said.